Dasher Neuroscience Holdings Inc. (TPEx: 7829) announced it has completed patient enrollment in a global, multi-center Phase 2 clinical trial ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE